Trial Profile
An International Phase 3, Randomized, Double-Blind, Active (Tolterodine)-Controlled Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 May 2023
Price :
$35
*
At a glance
- Drugs Vibegron (Primary) ; Tolterodine
- Indications Overactive bladder
- Focus Adverse reactions; Registrational
- Acronyms Empowur
- Sponsors Urovant Sciences
- 22 May 2023 According to Pierre Fabre media release, based on positive data from this study, EU marketing authorization application procedure for Vibegron in overactive bladder have been started.
- 10 Sep 2022 Results of post hoc subgroup analysis assessing the long-term safety and efficacy of vibegron for overactive bladder syndrome in patients greater than equal to 65 years old, presented at the 52nd Annual Meeting of the International Continence Society.
- 16 May 2022 Results of an analysis assessing long-term patient reported outcomes from EMPOWUR extension trial presented at the 117th Annual Meeting of the American Urological Association